These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
10. [Bone disease in chronic renal failure and its modern therapy]. Dusilová Sulková S Vnitr Lek; 2011; 57(7-8):620-5. PubMed ID: 21877595 [TBL] [Abstract][Full Text] [Related]
11. Effects of the impairment of renal function and of the pH of gastric secretion on the efficacy of Al(OH)3 to reduce serum inorganic phosphorus. Barsotti G; Lazzeri M; Polloni A; Morelli E; Giovannetti E; Lupetti S; Cupisti A; Dani L; Giovannetti S Adv Exp Med Biol; 1986; 208():493-9. PubMed ID: 3565160 [No Abstract] [Full Text] [Related]
12. Renal osteodystrophy: past and future. Slatopolsky E; Lopez-Hilker S; Dusso A; Brown A; Delmez J; Martin K Contrib Nephrol; 1990; 78():38-45; discussion 45-6. PubMed ID: 2225842 [No Abstract] [Full Text] [Related]
13. [Effects of aluminum gels on renal osteodystrophy caused by chronic hemodialysis. Increase in the total surface of osseous resorption in anephric patients]. Fournier A; Tunchot S; Bedrossians J; Idatte JM; Bordier P Sem Hop; 1974 Nov; 50(45):2803-10. PubMed ID: 4375854 [No Abstract] [Full Text] [Related]
14. The radiographic spectrum of renal osteodystrophy. Molpus WM; Pritchard RS; Walker CW; Fitzrandolph RL Am Fam Physician; 1991 Jan; 43(1):151-8. PubMed ID: 1986484 [TBL] [Abstract][Full Text] [Related]
15. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3. Madsen S Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650 [No Abstract] [Full Text] [Related]
16. CKD-Mineral Bone Disorder in Stage 4 and 5 CKD: What We Know Today? Melamed ML; Buttar RS; Coco M Adv Chronic Kidney Dis; 2016 Jul; 23(4):262-9. PubMed ID: 27324680 [TBL] [Abstract][Full Text] [Related]
17. [Opinionnaire survey on the treatment of renal osteodystrophy in Japan]. Morii H Nihon Jinzo Gakkai Shi; 1983 Apr; 25(4):439-47. PubMed ID: 6620696 [No Abstract] [Full Text] [Related]
18. Hypophosphataemia and osteomalacia in haemodialysis patients not taking phosphate binders. Ahmed KY; Varghese Z; Meinhard EA; Baillod RA; Skinner RK; Wills MR; Moorhead JF Adv Exp Med Biol; 1977; 81():581-90. PubMed ID: 899942 [No Abstract] [Full Text] [Related]
19. Suppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide. Mak RH; Turner C; Thompson T; Powell H; Haycock GB; Chantler C Br Med J (Clin Res Ed); 1985 Sep; 291(6496):623-7. PubMed ID: 3928054 [TBL] [Abstract][Full Text] [Related]
20. [Influence of vitamin D therapy on renal osteodystrophy in children (author's transl)]. Bulla M; Stock GJ; Delling G; Hofmann H; Offermann G Klin Wochenschr; 1980 Mar; 58(5):237-47. PubMed ID: 6249957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]